Trading ideas: Capital A, FGV, Malakoff, LFE, Hektar REIT, Favelle Favco, Life Water, Ivory, Masteel, Ygl, Jetson, Hartalega, Heineken, UOA REIT, Dufu
Capital A Bhd intends to raise at least USD200.0mn from a secondary listing in Hong Kong as the parent of AirAsia looks to tap mainland Chinese investors and accelerate growth, according to its chief executive officer Tan Sri Tony Fernandes.
FGV Holdings Bhd said it has not received any formal notice from the Federal Land Development Authority with regards to a takeover offer, as published in a news report recently.
Malakoff Corporation Bhd has successfully issued its inaugural RM250.0mn ASEAN Sustainability Sustainable and Responsible Investment Sukuk Murabahah under its RM1.2bn Islamic Medium-Term Notes Programme.
LFE Corporation Bhd has accepted the letter of award from Gamuda Engineering Sdn Bhd for mechanical, electrical and plumbing fit-out work at the hyperscale data centre in Elmina Business Park 1A, Selangor, worth RM50.6mn.
Hektar Real Estate Investment Trust has collaborated with Samaiden Group Bhd on a solar deal, aligning with Malaysia's renewable energy transition and long-term carbon reduction targets.
Favelle Favco Bhd 's subsidiaries, Favelle Favco Cranes Pty Limited and Favelle Favco Cranes (M) Sdn Bhd have received RM43.9mn purchase orders for the supply of offshore and tower cranes.
Life Water Bhd is building a new drinking water manufacturing line at its Sandakan Sibuga Plant 1, which will have an annual production capacity of 178mn litres.
Practice Note 17 company Ivory Properties Group Bhd is selling a double-storey detached commercial building known as The Birch House in George Town, Penang for RM18.0mn to settle its bank borrowings.
Malaysia Steel Works (KL) Bhd has signed a MoU with Ace Gases Marketing Sdn Bhd and Universiti Tunku Abdul Rahman to deploy innovative carbon capture, utilisation, and storage technologies.
YGL Convergence Bhd has announced the resignation of Chengco PLT as its auditor due to suspension of latter's registration by the Audit Oversight Board of the Securities Commission Malaysia.
Kumpulan Jetson Bhd has received a writ of summons from three minority shareholders who are seeking a court order to void a requisition notice dated April 23, 2025, and to halt any corporate action based on it.
Hartalega Holdings Bhd posted a lower net profit of RM14.5mn for 4QFY25 versus RM14.9mn a year ago as lower non-operating income offset gains from improved operations.
Heineken Malaysia Bhd reported a net profit of RM122.2mn for 1QFY25, largely unchanged from RM122.5mn a year earlier, supported by lower interest expenses, effective cost control and improved financial efficiency.
UOA Real Estate Investment Trust's net profit for 1QFY25 fell 14.6% YoY to RM10.0mn from RM11.7mn a year ago, due to higher operating expenses.
Dufu Technology Corporation Bhd's net profit for 1QFY25 surged 57.4% YoY to RM7.0mn from RM4.4mn a year ago, thanks to higher sales of hard disk drive components.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ — Brii Biosciences Limited ('Brii Bio,' stock code: a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ('Joincare Group'). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: 'The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections.' Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, 'The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options.' About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ('Brii Bio', stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
The Sun
an hour ago
- The Sun
Li Li of Next Capital Named in Caijing Magazine's 'Top 50 Global Chinese Venture Capitalists'
NEW YORK, USA - Media OutReach Newswire - 3 July 2025 - Recently, Li Li, Founding Partner of Next Capital, was honored as one of Caijing Magazine's 'Top 50 Global Chinese Venture Capitalists'. Awarded by Caijing, an authoritative media platform focusing on global industry-finance integration, this accolade highlights Chinese investment leaders who have consistently generated excess returns in major global VC markets and driven technological transformation and industrial innovation through forward-looking strategic deployments. Since entering the technology investment field in 2011, Li Li has led angel or early-stage investments in companies such as LexinFintech (NASDAQ: LX), TuanChe Limited (NASDAQ: TC), Tiger Brokers (NASDAQ: TIGR), Niuguwang, PingCAP, HOSE, 77irCloud, Caibeike, Lockin, Krazybee (India), Chi Forest, Walnut Coding, PandaRemit, ShopLazza, XellSmart, Weiming Shiguang, and others. She is also the founder of Xiaofanzhuo, a leading Chinese venture capital service platform. Before transitioning to early-stage tech investment, Li Li had a decade of experience in tech financial media, serving as Editorial Board Member and Chief Reporter for the Chinese edition of Information Week, and Deputy Editor-in-Chief of Ceocio China. Notably, she is the only Chinese journalist to have conducted an exclusive interview with Amazon founder Jeff Bezos. This background has endowed Li Li with profound insights into technology-driven business innovation. Her belief in technological advancement has shaped her early-stage investment style over the past 15 years. 'We seek out each generation of young people who use tech innovation to change the world. Every era produces its own heroes' Li Li said. The global emergence of Chinese venture capitalists reflects not only China's economic ascent and increasing international presence, but also the sharp instinct and execution of Chinese entrepreneurs and investors in the global innovation ecosystem. Next Capital looks forward to partnering with more innovators to 'Discover the Next Big Thing.' Founded in 2017, Next Capital is an early-stage investment fund focused on the technology sector. As 'the first money for innovators,' the firm is committed to backing technology-driven business innovation and partnering with visionary founders to shape the future. Its investment portfolio spans artificial intelligence, hard technology, digital healthcare, global tech expansion, biotech & life sciences, enterprise services, cloud-native technologies, specialized & innovative sectors, robotics, etc. Its portfolio features a number of standout companies such as Chi Forest, PandaRemit, FINDING UNICORN, ShopLazza, XellSmart, Atantares, Weiming Shiguang, GLZHealth, SIBIONICS, among other forward-thinking enterprises. Next Capital's venture support initiatives—including 'NEXT Entrepreneurship Banquet,' 'NEXT Innovation Camp,' and 'NEXT LEAGUE'—are designed to provide systematic, end-to-end support for entrepreneurs from startup to IPO. These programs have fostered a dynamic ecosystem of new-economy Chinese entrepreneurs, reaching and influencing over 80,000 individuals across Greater China, North America, Europe, Singapore, and beyond.
New Straits Times
an hour ago
- New Straits Times
Gold heads for weekly gain on US fiscal concerns after tax-cut bill
NEW YORK: Gold held steady on Friday, poised for a weekly gain as US President Donald Trump's tax-cut and spending bill passed in Congress, raising fiscal concerns, though stronger-than-expected US jobs data capped bullion's gains. FUNDAMENTALS Spot gold was flat at US$3,328.36 per ounce, as of 0029 GMT. Bullion is up 1.7 per cent this week. US gold futures edged down 0.1 per cent to US$3,337.90. Trump's tax-cut legislation cleared its final hurdle in the US Congress on Thursday, as the Republican-controlled House of Representatives narrowly approved a massive package that would fund his domestic agenda and push millions of Americans off health insurance. The labor market data on Thursday showed US firms added a more-than-expected 147,000 jobs in June and the unemployment rate unexpectedly fell to 4.1 per cent. Solid job gains bolstered the case for the Federal Reserve to hold interest rates steady. Fed funds futures traders are now pricing in a 50-basis-point rate cut this year, starting October. Meanwhile, Trump announced that letters specifying tariff rates on imports would begin being sent out Friday, signaling a shift from earlier pledges to negotiate individual trade deals. Non-yielding bullion, considered a safe-haven asset during geopolitical and economic uncertainties, tends to perform well in a low-interest-rate environment. On Ukraine, Trump said a phone call with Russian President Vladimir Putin yielded no progress in resolving the conflict, while the Kremlin stated that Moscow would continue addressing the "root causes" of the crisis. Platinum prices have limited room to rise further after a record quarterly rally, analysts and traders said, with Chinese imports expected to soften and South African output likely to recover against a backdrop of still-muted auto sector demand. Spot silver fell 0.3 per cent to US$36.73 per ounce, platinum rose 0.8 per cent to US$1,378.30 and palladium was up 0.1 per cent at US$1,137.94. All three metals were headed for weekly gains.
